Assessment of cigarette smoke particle deposition within the Vitrocell® exposure module using quartz crystal microbalances

Chemistry Central Journal

Jason Adamson¹  David Thorne¹  Annette Dalrymple¹  Debbie Dillon¹  Clive Meredith¹ 

[1] British American Tobacco, Group R&D, Southampton, SO15 8TL, UK

关键词: Vitrocell®;    In vitro whole smoke exposure systems;    Tobacco smoke;    Quartz crystal microbalance;    QCM;    Particle deposition;    Dosimetry;   

Others  :  795612
DOI  :  10.1186/1752-153X-7-50

 received in 2012-12-18, accepted in 2013-03-06,  发布年份 2013

【 摘 要 】

Background

Cigarette smoking is a cause of a variety of serious diseases, and to understand the toxicological impact of tobacco smoke in vitro, whole smoke exposure systems can be used. One of the main challenges of the different whole smoke exposure systems that are commercially available is that they dilute and deliver smoke in different ways, limiting/restricting the cross-comparison of biological responses. This is where dosimetry – dose quantification – can play a key role in data comparison. Quartz crystal microbalance (QCM) technology has been put forward as one such tool to quantify smoke particle deposition in vitro, in real-time.

Results

Using four identical QCMs, installed into the Vitrocell® mammalian 6/4 CF Stainless exposure module, we were able to quantify deposited smoke particle deposition, generated and diluted by a Vitrocell® VC 10 Smoking Robot. At diluting airflows 0.5-4.0 L/min and vacuum flow rate 5 ml/min/well through the exposure module, mean particle deposition was in the range 8.65 ± 1.51 μg/cm²-0.72 ± 0.13 μg/cm². Additionally, the effect of varying vacuum flow rate on particle deposition was assessed from 5 ml/min/well - 100 ml/min/well. Mean deposited mass for all four airflows tested per vacuum decreased as vacuum rate was increased: mean deposition was 3.79, 2.75, 1.56 and 1.09 μg/cm² at vacuum rates of 5, 10, 50 and 100 ml/min/well respectively.

Conclusions

QCMs within the Vitrocell® exposure module have demonstrated applicability at defining particle dose ranges at various experimental conditions. This tool will prove useful for users of the Vitrocell® system for dose–response determination and QC purposes.

【 授权许可】

   
2013 Adamson et al.; licensee Chemistry Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Aufderheide M, Scheffler S, Möhle Halter B, Hochrainer D: Analytical in vitro approach for studying cyto- and genotoxic effects of particulate airborne material. Anal Bional Chem 2011, 401:3213-3220.
• [2]Zhang W, Case S, Bowler RP, Martin RJ, Jiang D, Chu W: Cigarette smoke modulates PGE2 and host defence against Moraxella catarrhalis infection in human airway epithelial cells. Respirology 2011, 16:508-516.
• [3]Okuwa K, Tanaka M, Fukano Y, Nara H, Nishijima Y, Nishino T: In vitro micronucleus assay for cigarette smoke using a whole smoke exposure system: a comparison of smoking regimens. Exp Toxicol Pathol 2010, 62:433-440.
• [4]St-Laurent J, LaI P, Boulet LP, Bissonnette E: Comparison of two in vitro models of cigarette smoke exposure. Inhal Toxicol 2009, 21:1148-1153.
• [5]Clunes L, Bridges B, Alexis N, Tarran R: In vivo versus in vitro airway surface liquid nicotine levels following cigarette smoke exposure. J Anal Toxicol 2008, 32(3):201-207.
• [6]Maunders H, Patwardhan S, Phillips J, Clack A, Richter A: Human bronchial epithelial cell transcriptome: gene expression changes following acute exposure to whole cigarette smoke in vitro. American Journal of Physiology - Lung Cellular and Molecular Physiology 2007, 292:L1248-L1256.
• [7]Olivera DS, Boggs SE, Beenhouwer C, Aden J, Knall C: Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro. Inhal Toxicol 2007, 19:13-22.
• [8]Beisswenger C, Platz J, Seifart C, Vogelmeier C, Bals R: Exposure of Differentiated Airway Epithelial Cells to Volatile Smoke in vitro. Respir 2004, 71:402-409.
• [9]Adamson J, Azzopardi D, Errington G, Dickens C, McAughey J, Gaca MD: Assessment of an in vitro whole cigarette smoke exposure system: The Borgwaldt RM20S 8-syringe smoking machine. Chem Cent J 2011, 5:50. BioMed Central Full Text
• [10]Scian MJ, Oldham MJ, Kane DB, Edmiston JS, McKinney WJ: Characterization of a whole smoke in vitro exposure system (Burghart Mimic Smoker-01). Inhal Toxicol 2009, 21:234-243.
• [11]Scian MJ, Oldham MJ, Miller JH, Kane DB, Edmiston JS, McKinney WJ: Chemical analysis of cigarette smoke particulate generated in the MSB-01 in vitro whole smoke exposure system. Inhal Toxicol 2009, 21:1040-1052.
• [12]Nara H, Fukano Y, Nishino T, Aufderheide M: Detection of the cytotxicity of water-insoluble fraction of cigarette smoke by direct expopsure to cultured cells at an air-liquid interface. Exp Toxic Pathol 2012,  . in press
• [13]Phillips J, Kluss B, Richter A, Massey E: Exposure of bronchial epithelial cells to whole cigarette smoke: assessment of cellular responses. Alternative to Laboratory Animals - ATLA 2005, 33:239-248.
• [14]Aufderheide M, Mohr U: CULTEX - a new system and technique for the cultivation and exposure of cells at the air/liquid interface. Exp Toxicol Pathol 1999, 51:489-490.
• [15]Kim JS, Peters TM, O’Shaughnessy PT, Adamcakova-Dodd A, Thorne PS: Validation of an in vitro system for toxicity assessment of air delivered nanomaterials. Toxicol in Vitro 2012, 27(1):164-173.
• [16]Deschl U, Vogel J, Aufderheide M: Development of an in vitro exposure model for investigating the biological effects of therapeutic aerosols on human cells from the respiratory tract. Exp Toxicol Pathol 2011, 63:593-598.
• [17]Persoz C, Leleub C, Acharda S, Fasseuc M, Menottib J, Meneceurb P, Momasa I, Derouinb F, Seta N: Sequential air–liquid exposure of human respiratory cells to chemical and biological pollutants. Toxicol Letters 2011, 207:53-59.
• [18]Aufderheide M, Knebel JW, Ritter D: Novel approaches for studying pulmonary toxicity in vitro. Toxicol. Letters. 2003, 140–141:205-211.
• [19]Bakand S, Hayes A: Troubleshooting methods for toxicity testing of airborne chemicals in vitro. J Pharmacol Toxicol Methods 2010, 61:76-85.
• [20]Kaur N, Lacasse M, Roy JP, Cabral JL, Adamson J, Errington G, Waldron KC, Gaca M, Morin A: Evaluation of precision and accuracy of the Borgwaldt RM20S® smoking machine designed for in vitro exposure. Inhal Toxicol 2010, 22:1174-1183.
• [21]Adam T, Mitschke S, Streibel T, Baker RR, Zimmermann R: Quantitative Puff-by-Puff-Resolved Characterization of Selected Toxic Compounds in Cigarette Mainstream Smoke. Chem Res Toxicol 2006, 19:511-520.
• [22]Adamson J, Hughes S, Azzopardi D, McAughey J, Gaca M: Real-time assessment of cigarette smoke particle deposition in vitro. Chem Cent J 2012, 6:98. BioMed Central Full Text
• [23]Paur HR, Cassee FR, Teeguarden J, Fissan H, Diabate S, Aufderheide M, Kreyling WG, Hänninen O, Kasper G, Riediker M, Rothen-Rutishauser B, Schmid O: In-vitro cell exposure studies for the assessment of nanoparticle toxicity in the lung - A dialog between aerosol science and biology. J Aerosol Sci 2011, 42:668-692.
• [24]Yuwono AS, Lammers PS: Odor pollution in the environment and the detection instrumentation. Agricultural Engineering International: the CIGR Journal of Scientific Research and Development 2004, 6:1-33.
• [25]Peng B, NingNing L, Wang LM, Zhang WK, Niu ZW, Wang Q, Su ZH: Self-assembly of anisotropic tobacco mosaic virus nanoparticles on gold substrate. SCIENCE CHINA Chem 2011, 54(1):137-143.
• [26]Klepeis NE, Ott WK, Switzer P: Real-time measurement of outdoor tobacco smoke particles. J Air & Waste Management Association 2007, 57:522-534.
• [27]Yeh AC, Turner RS, Jones RK, Muggenburg BA, Lundgren DL, Smith JP: Characterisation of aerosols produced during surgical procedures in hospitals. Aerosol Science and Technology 1995, 22:151-216.
• [28]Barnes PJ: New concepts in chronic obstructive pulmonary disease. Annual Review of Medicine 2003, 54:113-129.
• [29]Levitz JS, Bradley TP, Golden AL: Overview of smoking and all cancers. Medical Clinics of North America 2004, 2004:88.
• [30]Perfetti TA, Rodgman A: The Complexity of Tobacco and Tobacco Smoke. Beitr Tabakforsch Int 2011, 24:215-232.
• [31]Fowles J, Dybing E: Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob Control 2003, 12:424-430.
• [32]Adamson J, Haswell LE, Phillips G, Gaça MD: In Vitro Models of Chronic Obstructive Pulmonary Disease (COPD). In Bronchitis. Edited by Ignacio Martin-Loeches MD. : InTech; 2011. ISBN 978-953-307-889-2
• [33]Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG: Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments. Toxicol Sci 2007, 95(2):300-312.
• [34]Aufderheide M, Knebel JW, Ritter D: An improved in vitro model for testing the pulmonary toxicity of complex mixtures such as cigarette smoke. Exp Toxic Pathol 2003, 55:51-57.
• [35]Kaur N, Cabral JL, Morin A, Waldron K: Headspace stir bar sorptive extraction-gas chromatography/mass spectrometry characterization of the diluted vapor phase of cigarette smoke delivered to an in vitro cell exposure chamber. Journal of Chromatography A 2011, 1218:324-333.
• [36]Mülhopt S, Diabate S, Krebs T, Weiss C, Paur HR: Lung toxicity determination by in vitro exposure at the air liquid interface with an integrated online dose measurement. J Phys Conf Ser 2009, 170:-012008.